Begin main content

Positron Emission Tomography-Computed Tomography for Rheumatology Indications: Diagnostic Accuracy, Clinical Utility, Cost-Effectiveness, and Evidence-Based Guidelines

Last updated: November 6, 2018
Project Number: RB1275-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the diagnostic test accuracy of positron emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis (GCA) or Takayasu’s vasculitis?
  2. What is the clinical utility of positron emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis (GCA) or Takayasu’s vasculitis?
  3. What is the cost-effectiveness of positron emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis or Takayasu’s vasculitis?
  4. What are the evidence-based guidelines associated with the use of positron-emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis (CGA) or Takayasu’s vasculitis?

Key Message

Four non-randomized studies were identified regarding fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) for patients with Giant Cell Arteritis (GCA). No evidence was identified for Takayasu's vasculitis. No economic evaluations or evidence-based guidelines were identified.